MESO vs. RLAY, PRME, RGNX, CRGX, HUMA, PROK, KYTX, IMTX, HLVX, and EXAI Should you be buying Mesoblast stock or one of its competitors? The main competitors of Mesoblast include Relay Therapeutics (RLAY), Prime Medicine (PRME), REGENXBIO (RGNX), CARGO Therapeutics (CRGX), Humacyte (HUMA), ProKidney (PROK), Kyverna Therapeutics (KYTX), Immatics (IMTX), HilleVax (HLVX), and Exscientia (EXAI). These companies are all part of the "biological products, except diagnostic" industry.
Relay Therapeutics (NASDAQ:RLAY ) and Mesoblast (NASDAQ:MESO ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, valuation, profitability, dividends, risk, media sentiment and institutional ownership.
Do insiders and institutionals have more ownership in RLAY or MESO?
97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 4.3% of Relay Therapeutics shares are held by company insiders. Comparatively, 18.8% of Mesoblast shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Which has stronger earnings & valuation, RLAY or MESO?
Mesoblast has lower revenue, but higher earnings than Relay Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.
Which has more volatility and risk, RLAY or MESO?
Relay Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Comparatively, Mesoblast has a beta of 3.45, indicating that its share price is 245% more volatile than the S&P 500.
Does the MarketBeat Community believe in RLAY or MESO?
Mesoblast received 364 more outperform votes than Relay Therapeutics when rated by MarketBeat users. Likewise, 70.45% of users gave Mesoblast an outperform vote while only 60.94% of users gave Relay Therapeutics an outperform vote.
Do analysts recommend RLAY or MESO?
Relay Therapeutics currently has a consensus price target of $22.20, indicating a potential upside of 234.34%. Mesoblast has a consensus price target of $13.67, indicating a potential upside of 85.94%. Given Mesoblast's stronger consensus rating and higher possible upside, equities analysts clearly believe Relay Therapeutics is more favorable than Mesoblast.
Is RLAY or MESO more profitable?
Mesoblast has a net margin of 0.00% compared to Mesoblast's net margin of -1,263.49%. Relay Therapeutics' return on equity of 0.00% beat Mesoblast's return on equity.
Does the media prefer RLAY or MESO?
In the previous week, Mesoblast had 3 more articles in the media than Relay Therapeutics. MarketBeat recorded 4 mentions for Mesoblast and 1 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.26 beat Mesoblast's score of 0.09 indicating that Mesoblast is being referred to more favorably in the news media.
Summary Mesoblast beats Relay Therapeutics on 12 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Mesoblast Competitors List
Related Companies and Tools